Merck Reports Phase 2b Data for Ipilimumab in Ovarian cancer

Merck today announced Phase 2b results for ipilimumab in patients with ovarian cancer. The study demonstrated that ipilimumab achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of ovarian cancer and support the continued development of ipilimumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.